Abstract
Aircraft wastewater surveillance has been proposed as a novel approach to monitor the global spread of pathogens. Here we develop a computational framework to provide actionable information for designing and estimating the effectiveness of global aircraft-based wastewater surveillance networks (WWSNs). We study respiratory diseases of varying transmission potentials and find that networks of 10 to 20 strategically placed wastewater sentinel sites can provide timely situational awareness and function effectively as an early warning system. The model identifies potential blind spots and suggests optimization strategies to increase WWSNs effectiveness while minimizing resource use. Our findings highlight that increasing the number of sentinel sites beyond a critical threshold does not proportionately improve WWSNs capabilities, stressing the importance of resource optimization. We show through retrospective analyses that WWSNs can significantly shorten the detection time for emerging pathogens. The presented approach offers a realistic analytic framework for the analysis of WWSNs at airports.
Competing Interest Statement
SVS is a paid consultant at Verily. The authors declare no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was in part supported by the Bill & Melinda Gates Foundation INV-058220. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. We acknowledge support from the CDC-75D301Cl4810 contract and the cooperative agreement CDC-RFA-FT-23-0069 from the CDC's Center for Forecasting and Outbreak Analytics. GS acknowledges financial support from the Fonds de recherche du Qué;bec - Nature et technologies (project 313475). LHD is supported by the National Institutes of Health 2P20GM125498-06 Centers of Biomedical Research Excellence Award. AA acknowledges support from the Natural Sciences and Engineering Research Council of Canada (projects 2019-05183 and 2024-05626). The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the funding agencies, the CDC, or the U.S. Department of Health and Human Services of the United States.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Proprietary airline data are commercially available from the Official Aviation Guide (https://www.oag.com/) and International Air Transport Association (https://www.iata.org/) databases. The mechanistic GLEAM model is publicly available at http://www.gleamviz.org/.
